Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

Phase 1 Recruiting

78 enrolled

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

240 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07337525 2026-02-18

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

Phase 1 Recruiting

36 enrolled

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms

NCT06778863 2026-02-13

GUARDIAN-101

Phase 1 Recruiting

90 enrolled

BreastGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms

NCT06238479 2026-02-11

EXCEED

Phase 1 Recruiting

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT03740256 2026-02-06

VISTA

Phase 1 Recruiting

45 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

250 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT06465069 2026-01-22

NEXUS-01

Phase 1 Recruiting

420 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

NCT07359235 2026-01-22

Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)

Phase 1 Recruiting

29 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07277413 2026-01-20

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1 Recruiting

260 enrolled

GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT06529822 2026-01-13

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1 Recruiting

32 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05562791 2026-01-07

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Phase 1 Recruiting

20 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

168 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT07090499 2025-12-09

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Phase 1 Recruiting

310 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT04794699 2025-11-12

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase 1 Recruiting

180 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Recruiting

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting

30 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

NCT05683418 2025-07-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors

Phase 1 Recruiting

241 enrolled

GenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT06337084 2025-05-22

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Phase 1 Recruiting

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06617169 2025-05-21

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Phase 1 Recruiting

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06586255 2025-05-08

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Phase 1 Recruiting

10 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05839119 2025-03-21

TASUC-Neo

Phase 1 Recruiting

32 enrolled

Genitourinary

Urinary Bladder Neoplasms